Chronic Myelomonocytic Leukemia Completed Phase 2 Trials for Imatinib (DB00619)

Also known as: Chronic myelomonocytic leukaemia / Chronic myelomonocytic leukemia with failed remission / Leukemia, Myelomonocytic, Chronic

IndicationStatusPhase
DBCOND0028572 (Chronic Myelomonocytic Leukemia)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00079313Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous LeukemiaTreatment
NCT00171912Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesTreatment
NCT00039416Imatinib Mesylate in Treating Patients With MyelofibrosisTreatment
NCT00136409A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)Treatment